Englander Institute for Precision Medicine

Publications

Found 805 results
Author Title Type [ Year(Asc)]
2024
Kudman S, Semaan A, Assaad MAl, Gogineni S, M Martin L, Mathew S, Elemento O, Wilkes DC, Mosquera JMiguel.  2024.  Optimization of Fluorescence In Situ Hybridization Protocols in the Era of Precision Medicine.. Curr Protoc. 4(6):e1093.
Hanif SZ, Au CMCherie, Torregroza I, Jannath SY, Fabiha T, Bhinder B, Washburn M, Devost D, Liu S, Bhardwaj P et al..  2024.  The Orphan G Protein-Coupled Receptor GPR52 is a Novel Regulator of Breast Cancer Multicellular Organization.. bioRxiv.
Petralia F, Ma W, Yaron TM, Caruso FPia, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB et al..  2024.  Pan-cancer proteogenomics characterization of tumor immunity.. Cell. 187(5):1255-1277.e27.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X, Moyer J, M Martin L, Chandwani R, Elemento O et al..  2024.  A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.. Cell Stem Cell. 31(1):71-88.e8.
Naulin F, Guilbaud E, Galluzzi L.  2024.  PARP7 and nucleic acid-driven oncosuppression.. Cell Mol Immunol.
Rowdo FPMadorsky, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B et al..  2024.  Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.. Cancer Lett. 584:216608.
Wu Y, Foollee A, Chan AY, Hille S, Hauke J, Challis MP, Johnson JL, Yaron TM, Mynard V, Aung OH et al..  2024.  Phosphoproteomics-directed manipulation reveals SEC22B as a hepatocellular signaling node governing metabolic actions of glucagon.. Nat Commun. 15(1):8390.
Glass J, Elemento O.  2024.  The power and perils of large language models in haematology.. Br J Haematol.
San Pedro JManuel Bra, Aranda F, Buqué A, Galluzzi L.  2024.  Preface.. Methods Cell Biol. 185:xvii-xxiv.
Sun BB, Suhre K, Gibson BW.  2024.  Promises and challenges of populational proteomics in health and disease.. Mol Cell Proteomics. :100786.
Sinha NK, McKenney C, Yeow ZY, Li JJ, Nam KHong, Yaron-Barir TM, Johnson JL, Huntsman EM, Cantley LC, Ordureau A et al..  2024.  The ribotoxic stress response drives UV-mediated cell death.. Cell.
Vong KIoi, Lee S, Au KSing, T Crowley B, Capra V, Martino J, Haller M, Araújo C, Machado HR, George R et al..  2024.  Risk of meningomyelocele mediated by the common 22q11.2 deletion.. Science. 384(6695):584-590.
Halama A, Zaghlool S, Thareja G, Kader S, Muftah WAl, Mook-Kanamori M, Sarwath H, Mohamoud YAli, Stephan N, Ameling S et al..  2024.  A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes.. Nat Commun. 15(1):7111.
Nanaware PP, Khan ZN, Clement CC, Shetty M, Mota I, Seltzer ES, Dzieciatkowska M, Gamboni F, D'Alessandro A, Ng C et al..  2024.  Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load.. Cell Rep. 43(6):114311.
Schweickart A, Batra R, Neth BJ, Martino C, Shenhav L, Zhang AR, Shi P, Karu N, Huynh K, Meikle PJ et al..  2024.  Serum and CSF metabolomics analysis shows Mediterranean Ketogenic Diet mitigates risk factors of Alzheimer's disease.. NPJ Metab Health Dis. 2(1):15.
Altorki NK, Bhinder B, Borczuk AC, Elemento O, Mittal V, McGraw TE.  2024.  A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.. Cell Rep Med. :101438.
Sundaram L, Kumar A, Zatzman M, Salcedo A, Ravindra N, Shams S, Louie BH, S Bagdatli T, Myers MA, Sarmashghi S et al..  2024.  Single-cell chromatin accessibility reveals malignant regulatory programs in primary human cancers.. Science. 385(6713):eadk9217.
Cullati SN, Akizuki K, Chen J-S, Johnson JL, Yaron-Barir TM, Cantley LC, Gould KL.  2024.  Substrate displacement of CK1 C-termini regulates kinase specificity.. Sci Adv. 10(19):eadj5185.
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S et al..  2024.  Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.. Nat Commun. 15(1):2528.
Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S et al..  2024.  Three-dimensional regulatory hubs support oncogenic programs in glioblastoma.. bioRxiv.
Min D, Fiedler J, Anandasabapathy N.  2024.  Tissue-resident memory cells in antitumoral immunity and cancer immunotherapy.. Curr Opin Immunol. 91:102499.
Shah Y, Yang H, Mueller FB, Li C, Rahim SEGul, Varma E, Salinas T, Dadhania DM, Salvatore SP, Seshan SV et al..  2024.  Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.. Kidney Int. 105(2):347-363.
Sternberg CN, Freedland SJ, George DJ, Morgans AK.  2024.  Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale.. Clin Genitourin Cancer. 22(6):102171.
Markowski MC, Sternberg CN, Wang H, Wang T, Linville L, Marshall CH, Sullivan R, King S, Lotan TL, Antonarakis ES.  2024.  TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.. Oncologist.
Newman LA, Chen Y, Martini R, Demaria S, Formenti S, Elemento O, Davis MB.  2024.  Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women.. JAMA Surg.